The company said it had already seen the biggest improvement in patients who had not already adjusted to the natural response to the infection.
The treatment also showed positive trends in reducing medical visits of patients, none of whom were sick enough to be hospitalized at the start of the hearing, the company said. The numbers were low in this initial data release and the peer review of the data has not yet taken place. Only topline data was available in the news from the company.
A company spokesman said the data validates the treatment as a therapeutic alternative to the natural response to the virus.
Merazo said what was clear to him was that the study characterized patients by their immune responses before treatment and determined who did and did not benefit.
“What I find interesting is that it shows that antibodies really do matter and that the spike protein antibody was really helpful, especially when people were making the antibodies themselves.” “Whether it’s antibody therapy or a vaccine that targets this protein, it looks like we’re on the right track. I think it’s really encouraging.”
She was also encouraged by the reduction in the amount of virus in people’s throats, which in principle could reduce the risk of infecting others. “If it ends and you can treat people as early as possible and really reduce the viral load in the nasopharynx, and they look less contagious, it will be very helpful,” Merezo said.
Because the company published this information not as a scientific report, but in a published publication, it is not clear who got into the study and how much they were reflected in the population. Many more people will have to be tested for treatment to make sure it works well. Scientists will also want to know more about how many patients who received treatment need to be hospitalized.
Regeneron’s co-founder Dr. “We don’t have that information today, but we will,” Leonard Schaefer told CNN. “We have already learned that the viral load is higher in hospitalized patients, indicating that they are not trying to have an adequate immune response. So we hope we will be able to see the same thing with those patients.”
Schliffer is “very encouraged” by these preliminary results.
“It has come exactly the way we expect it to work,” Schliffer said.
“It feels safe, and it’s headed in the right direction in terms of reducing the virologic load and seems to have an initial relationship with fewer symptoms and fewer hospitalizations,” Hoyen said. “But again, they have a lot of patients to learn for sure.”
Cocktail antibody therapy uses two or more lab-engineered antibodies. Regeneran’s cocktail contains a monoclonal antibody that targets spike proteins used to drill into healthy cells, and another antibody that targets different parts of the novel coronavirus. With two, the hope is that the viral replica should be trapped and stopped.
“They seem to have gotten positive results and this antibody cocktail dose reduces the time patients get sick, especially patients who could not mount their own antibody response.” “They’ll have to do more human experiments and bigger experiments to really make sure.”
Former executive CDC director, who is now head of the Robert Wood Johnson Foundation, Dr. Richard Besser said it makes sense that the treatment the patient gives antibodies would help the immune system, but he said there would be no holes or difficulties in the peer review. .
“I will stop judging this until we see the data,” Besser said. “You know these preliminary results that keep coming out in press releases from companies, they tell me more about science, more about share prices, more about stock prices.”
Gomerman, Marazo and Hoyne think that antibody therapy may be a real help in a patient population that does not produce a real immune response to the vaccine, such as nursing homes or other elderly people. Treatment can also be helpful during the transition period, before everyone is vaccinated.
Regeneron said there would be more information from the trial, from trials involving hospitalized patients, and from antibiotic cocktail testing as a remedy for people with Covid-19 who had contact with someone in their household.
Scliff said Regeneran is in talks with regulators about the results to see if U.S. Whether the Food and Drug Administration will consider drug emergency authorization. They have additional data that the company will submit for formal approval.
Regenron co-founder George Yankopoulos said during a call with shareholders on Tuesday that regulators have decided to determine whether this is enough information to make this therapeutic intervention available to patients as soon as possible.
“I think it’s worth discussing with regulatory authorities because of all these social implications.”
“We think there’s a lot of evidence here that suggests this is a therapeutic remedy that can really benefit a lot of individuals and patients.”